Similarly, neutrophils harvested from lymphoma patients 3 days after initiation of treatment with ibrutinib or acalabrutinib displayed defective TLR2-, FcγR-, and Dectin-1-mediated ROS production relative to their preBTKi treatment baseline (Figure 6F). The gene discussed is CLEC7A; the disease is lymphoma.